Bioalliance PharmaAct Nom. Cat-P News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.06.14	Bioalliance Pharma and Topotarget Shareholders Approve Proposed Cross-Border Merger to Create Onxeo (Businesswire)
25.06.14	BioAlliance Pharma : Execution of a License Agreement with EMS for Sitavig® in Brazil (Businesswire)
20.06.14	Merger Plan with Topotarget: BioAlliance Pharma Has Received Pre-Approval for the Secondary Listing of the Shares of the Merged Company on NASDAQ OMX Copenhagen (Businesswire)
10.06.14	BioAlliance Pharma Strengthens Livatag® pAtent Protection in Japan Until 2032 (Businesswire)
10.06.14	BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at May 31, 2014 (Businesswire)
21.05.14	Definitive Merger Plan between BioAlliance Pharma and Topotarget (Businesswire)
19.05.14	BioAlliance Pharma SA: Livatag® Receives Fast Track Designation From the FDA for the Treatment of Primary Liver Cancer (Businesswire)
12.05.14	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2014 (Businesswire)
05.05.14	BioAlliance Pharma Announces Major Achievements on Validive® (Businesswire)
30.04.14	BioAlliance Pharma SA: Quarterly information as of March 31, 2014 (Businesswire)
29.04.14	BioAlliance Pharma Publishes Its First Shareholder Newsletter (Businesswire)
16.04.14	BioAlliance Pharma and Topotarget Enter into Merger Agreement to Create a Leading Orphan Oncology Company (Businesswire)
14.04.14	BioAlliance Pharma Announces a New Positive DSMB Recommendation to Continue Its Phase III Clinical Trial with Livatag® in Primary Liver Cancer (Businesswire)
08.04.14	BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions (Businesswire)
08.04.14	BioAlliance Pharma SA : Publication of the 2013 Registration Document (Businesswire)
03.04.14	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at March 31, 2014 (Businesswire)
02.04.14	BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea (Businesswire)
01.04.14	BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig® (Businesswire)
31.03.14	BioAlliance Pharma Collaborates with Penn Pharma on the Industrial Development of Validive® (Businesswire)
28.03.14	BioAlliance Pharma announces participation in the Smallcap Event On April 7th and 8th 2014 in Paris (GlobeNewswire)
28.03.14	BioAlliance Pharma Announces Participation in the Smallcap Event on April 7th and 8th 2014 in Paris (Businesswire)
19.03.14	BioAlliance Pharma: Sitavig® Licensing Strategy (Businesswire)
27.02.14	BioAlliance Pharma Provides Updates on Its Major Achievements and Reports 2013 Consolidated Financial Results (Businesswire)
18.02.14	BioAlliance Pharma SA: Strengthening and extension of the industrial protection of Livatag® until 2031 (Businesswire)
05.02.14	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at January 31, 2014 (Businesswire)
04.02.14	BioAlliance Pharma’s Partner, Sosei, Announces a Partnership With FUJIFILM Pharma for Commercialization Rights for Loramyc® in Japan (Businesswire)
23.01.14	BioAlliance Pharma : FDA Grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the Prevention and Treatment of Oral Mucositis Induced by Anticancer Treatments (Businesswire)
13.01.14	BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at December 31, 2013 (Businesswire)
04.12.13	BioAlliance Pharma: Approval to start ReLive (Livatag®) Phase III Clinical Trial in Primary Liver Cancer in the U.S. and Germany (Businesswire)
04.12.13	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2013 (Businesswire)
14.11.13	BioAlliance Pharma : Quarterly information as of September 30, 2013 (Businesswire)
14.11.13	BioAlliance Pharma Strengthens Sitavig Patent Protection with New U.S. and South Korean issued Patents (Businesswire)
06.11.13	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2013 (Businesswire)
22.10.13	BioAlliance Pharma Announces Third Positive DSMB Recommendation to Continue Its Phase III Clinical Trial with Livatag® in Primary Liver Cancer (Businesswire)
22.10.13	BioAlliance Pharma launches its new website (Businesswire)
07.10.13	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at September 30, 2013 (Businesswire)
30.09.13	BioAlliance Pharma : First Meeting of the International Advisory Board on Oral Mucositis and Development of Validive® (Businesswire)
19.09.13	BioAlliance Pharma: Key milestones and consolidated accounts (Businesswire)
05.09.13	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at August 31, 2013 (Businesswire)
02.08.13	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at July 31, 2013 (Businesswire)
10.07.13	BioAlliance Pharma Expands and Strengthens Its Industrial Property Assets with Two Patent Grants (Businesswire)
03.07.13	BioAlliance Pharma Receives €4.3 Million in Funding from bpifrance (ex OSEO) To Accelerate the Industrial Development of Livatag(R) (Businesswire)
09.01.13	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at December 31, 2012 (Businesswire)
07.01.13	BioAlliance Pharma Announces the Launch of Oravig® in the United States by Its New Partner, Vestiq Pharmaceuticals (Businesswire)
03.01.13	BioAlliance Pharma receives a guarantee from Coface to finance its export activities (Businesswire)
20.12.12	BioAlliance Pharma Announces the Registration of Sitavig® in European Countries (Businesswire)
19.12.12	BioAlliance Pharma: First Meeting of the DSMB of the ReLive Trial and Continuation without Modification of the Phase III Clinical Trial with Livatag® in Primary Liver Cancer (Businesswire)
06.12.12	BioAlliance Pharma: First meeting of the DSMB of the ReLive trial and continuation without modification of the Phase III clinical trial with Livatag® in primary liver cancer (Businesswire)
06.12.12	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2012 (Businesswire)
14.11.12	BioAlliance Pharma SA: Quarterly information as of September 30, 2012 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Bioalliance PharmaAct Nom. Cat-P

Aktien Top/Flop

Meistgelesene Nachrichten